Top Advances in Treatment for Benign Ovarian Tumor in 2024

Benign ovarian tumors are common gynecologic findings across the reproductive lifespan. Although benign, these lesions can cause symptoms (pelvic pain, bloating, menstrual irregularities), impaired fertility, torsion, or rupture, and some require surgical removal. In the United States more than 200,000 operations for adnexal masses are performed annually, but only a minority—approximately 10% in some series—represent malignant disease, emphasizing the importance of accurate diagnosis and appropriate selection of therapy to avoid unnecessary interventions while protecting patient safety and reproductive potential (BMC Ovarian Research, 2023). Advances in imaging, operative technique, minimally invasive therapies, fertility preservation, and perioperative care in 2024 have collectively improved individualized management of benign ovarian tumors.

This review summarizes contemporary classification and evaluation of benign ovarian tumors and then describes the principal treatment advances in 2024, with emphasis on evidence-based, patient-centered care and references to major clinical resources (ACOG, NIH/MedlinePlus, Mayo Clinic, Cleveland Clinic).

Background: Types and clinical presentation

Benign ovarian tumors include a heterogeneous group:

Functional cysts (follicular cysts, corpus luteum cysts) — usually physiologic and frequently resolve spontaneously.
Epithelial tumors: serous and mucinous cystadenomas (benign).
Germ cell tumors: mature cystic teratomas (dermoid cysts).
Sex cord–stromal tumors: e.g., thecomas, fibromas.
Endometriomas — cysts formed from ectopic endometrial tissue.
Paraovarian and paratubal cysts — arising adjacent to, but separate from, the ovary.

Clinical presentation ranges from incidental asymptomatic masses to progressive pelvic pain or pressure, acute pain with torsion or rupture, and infertility. The management objective is to distinguish masses that require urgent surgery from those amenable to observation or conservative therapy and to choose techniques that minimize morbidity and preserve ovarian function when appropriate.

For general information about ovarian cysts and adnexal masses, see resources from ACOG, MedlinePlus (NIH), Mayo Clinic, and Cleveland Clinic (ACOG; NIH/MedlinePlus; Mayo Clinic; Cleveland Clinic).

Evaluation and risk stratification

Appropriate treatment begins with accurate evaluation and risk stratification.

History and examination

A focused gynecologic history (menstrual pattern, pain characteristics, fertility desires, prior imaging or surgeries) and pelvic examination are foundational. Symptoms such as sudden severe pain suggest torsion or rupture and warrant urgent imaging.

Laboratory tests and biomarkers

Commonly used biomarkers include CA-125 and HE4. CA-125 may be elevated in many benign conditions (endometriosis, fibroids, inflammation) and is most useful in postmenopausal women as part of risk assessment. HE4 and multivariable algorithms such as the Risk of Ovarian Malignancy Algorithm (ROMA) can improve triage, but they are not definitive diagnostic tests and must be interpreted in clinical context.

Imaging

Transvaginal ultrasound (TVUS) is the imaging modality of choice for adnexal masses because of its accessibility, lack of ionizing radiation, and high resolution for pelvic structures. Advanced ultrasound techniques (Doppler flow, three-dimensional imaging, and standardized descriptors) and classification systems such as O-RADS (Ovarian-Adnexal Reporting and Data System) aid in distinguishing likely benign from suspicious lesions.

Magnetic resonance imaging (MRI), including diffusion-weighted imaging, is used when ultrasound findings are indeterminate or when detailed characterization of complex lesions is required. MRI can be particularly helpful for suspected endometriomas, dermoid cysts, or large multilocular masses.

For general guidance on diagnosis and initial management, see ACOG practice resources on adnexal masses and patient information on ovarian cysts from NIH/MedlinePlus, Mayo Clinic, and Cleveland Clinic (ACOG; NIH/MedlinePlus; Mayo Clinic; Cleveland Clinic).

Principles of management

Management options include:

Expectant management (active surveillance) for small, simple, likely functional cysts.
Medical therapy (e.g., hormonal suppression for recurrent functional cysts or endometriosis-related cysts).
Image-guided percutaneous procedures (aspiration, sclerotherapy) in select cases.
Minimally invasive surgery (cystectomy, oophorectomy, fertility-sparing approaches).
Emerging noninvasive ablative therapies in clinical trials.

Choice of therapy depends on symptomatology, mass characteristics, patient age and menopause status, tumor markers, fertility desires, and patient preference.

Below are the major advances and refinements in treatment that were prominent in 2024.

H2: Minimally invasive surgical techniques — refinement and wider adoption

Minimally invasive surgery remains the standard approach when operative management is indicated for benign ovarian tumors. In 2024, refinements in instrumentation, access strategies, and surgeon training have continued to reduce morbidity and improve recovery.

Laparoscopy and micro-laparoscopy

Laparoscopic cystectomy (ovarian-sparing cyst removal) is recommended for most benign lesions when feasible. Advances include:

Micro-laparoscopy (using 2–3 mm instruments) that further reduces incision size and wound pain.
Use of energy devices optimized to limit thermal spread and preserve ovarian tissue.
Suturing techniques and hemostatic agents that minimize damage to ovarian cortex and preserve ovarian reserve.

These refinements have been associated with shorter hospital stays, reduced postoperative pain, lower wound complication rates, and faster return to normal activities compared with laparotomy (open surgery).

Single-incision and reduced-port surgery

Single-incision laparoscopy (single-port) and reduced-port strategies are increasingly employed by experienced surgeons for selected cases, offering potential cosmetic advantages and equivalent outcomes in carefully selected patients.

Robotic-assisted laparoscopy

Robotic systems provide enhanced dexterity, three-dimensional visualization, and tremor filtration. In 2024 robotic-assisted cystectomy and adnexal surgery are used particularly for:

Large complex masses where precise dissection is required.
Patients with prior extensive abdominal surgery and adhesions.
Surgeons who prefer the ergonomics and fine control the system offers.

Evidence indicates comparable safety and efficacy to conventional laparoscopy for benign disease, although cost and availability remain considerations. ACOG and other specialty organizations emphasize surgeon experience and case selection when choosing robotic platforms (ACOG).

Intraoperative frozen section and specimen handling

When a mass has concerning features but malignancy is not definitive, intraoperative frozen section pathology can help determine the extent of surgery. For suspected benign lesions, careful specimen handling to prevent spillage (for example, use of endoscopic specimen bags) reduces the risk of chemical peritonitis or seeding in the rare event of unexpected malignancy.

Outcomes and ovarian preservation

Whenever possible, cystectomy with preservation of ovarian tissue is preferred in reproductive-age patients to maintain hormonal function and fertility. AMH (anti-Müllerian hormone) monitoring is increasingly used to counsel patients about the likely impact of surgery on ovarian reserve, and surgical techniques that minimize cortical excision and thermal injury are emphasized.

For evidence-based surgical recommendations and counseling points, see ACOG practice resources and patient materials at Mayo Clinic and Cleveland Clinic (ACOG; Mayo Clinic; Cleveland Clinic).

H2: Focused ultrasound and noninvasive ablation — emerging options

High-intensity focused ultrasound (HIFU) and other focused energy modalities have become established for uterine fibroids and are under investigation for other gynecologic applications. In 2024 there is growing interest in applying MR- or ultrasound-guided focused ultrasound to selected benign adnexal lesions as a noninvasive alternative to surgery.

What is HIFU?

HIFU delivers focused acoustic energy to a targeted tissue volume, producing thermal coagulative necrosis while sparing surrounding tissues. Guidance via MRI or diagnostic ultrasound enables real-time visualization and temperature monitoring for precise ablation.

Status and indications

HIFU is an approved and well-studied option for uterine fibroids in many centers; application to benign ovarian tumors is experimental and under investigation in early-phase clinical studies.
Potential indications under study include small symptomatic benign cystic lesions and recurrent lesions in patients who are poor surgical candidates or who desire avoidance of anesthesia.
Advantages would include an outpatient, incisionless procedure and preservation of ovarian tissue by avoiding surgical excision.

Limitations and safety considerations

Ovarian proximity to bowel and bladder increases procedural complexity; organ motion and acoustic windows may limit feasibility.
Long-term data on effectiveness, recurrence, and effects on ovarian function and fertility are limited.
HIFU for adnexal masses remains investigational and should be offered only within clinical trials or specialized centers with multidisciplinary expertise.

For more on HIFU in gynecology and ongoing research, consult national research databases and institutional clinical trials; general guidance on innovative ablative techniques can be found in review literature summarized by NIH resources (NIH/ClinicalTrials).

H2: Image-guided percutaneous and ablation therapies

Interventional radiology techniques are increasingly used as less-invasive alternatives in select patients.

Percutaneous aspiration and sclerotherapy

Simple cyst aspiration under ultrasound guidance can provide temporary symptom relief but is associated with high recurrence rates, particularly for complex cysts.
Sclerotherapy (injection of alcohol or other sclerosants) following aspiration reduces recurrence for some cystic lesions but is typically reserved for patients who decline or are poor candidates for surgery.
These procedures are most appropriate for simple cysts confirmed benign by imaging and in non-fertility-seeking patients or those who accept potential recurrence.

Percutaneous thermal ablation

Radiofrequency ablation (RFA), microwave ablation, and cryoablation have been used for ovarian lesions in limited series. Potential advantages include outpatient treatment and preservation of ovarian anatomy. However, data are limited and careful selection is critical.

Role in 2024 clinical practice

Image-guided percutaneous therapies are adjuncts for individualized care—useful for palliation or for patients who cannot undergo general anesthesia—but current guidelines emphasize that surgery remains the definitive treatment for symptomatic or suspicious lesions. Larger prospective studies are needed to define long-term outcomes and fertility effects.

Cleveland Clinic and Mayo Clinic provide patient-oriented descriptions of minimally invasive and image-guided options for ovarian cysts (Cleveland Clinic; Mayo Clinic).

H2: Improved diagnostic imaging and AI-assisted triage

Advances in imaging and the integration of artificial intelligence (AI) have improved preoperative discrimination between benign and malignant adnexal masses, thereby reducing unnecessary surgical interventions.

Standardized scoring systems

O-RADS (Ovarian-Adnexal Reporting and Data System) provides standardized ultrasound descriptors linked to management recommendations. Adoption of O-RADS improves interobserver consistency and clinical decision-making.
IOTA (International Ovarian Tumor Analysis) simple rules and logistic regression models remain validated tools for sonographic risk assessment.

MRI refinements

Diffusion-weighted imaging and contrast-enhanced sequences provide superior tissue characterization for indeterminate lesions.
MRI is particularly valuable for characterizing complex cystic masses, dermoid contents, and endometriomas.

Artificial intelligence and deep learning

AI algorithms trained on large ultrasound and MRI datasets can assist radiologists by flagging suspicious features and estimating malignancy risk.
In 2024 more centers are piloting AI-assisted triage tools that integrate imaging descriptors, laboratory values, and clinical history to generate risk scores used in multidisciplinary decision-making.
These tools are adjuncts and do not replace clinical judgment.

The combined effect of standardized reporting and AI tools is improved triage, fewer unnecessary surgeries for benign disease, and better allocation of specialty surgical resources. NIH-sponsored repositories and research consortia continue to evaluate the safety and generalizability of AI models in gynecologic imaging (NIH/NCBI).

H2: Biomarkers and molecular profiling — refining decision-making

Traditional biomarkers such as CA-125 have limitations, particularly in premenopausal women. In 2024, progress in biomarker panels and molecular profiling has supported more nuanced risk stratification.

HE4, CA-125, and ROMA

HE4 (human epididymis protein 4), alone or combined with CA-125 in the ROMA algorithm, improves discrimination of benign versus malignant adnexal masses, especially in postmenopausal women.
Use of these markers is most informative when used alongside imaging and clinical assessment, not as stand-alone tests.

Molecular and genomic approaches

For rare or indeterminate tumors, targeted sequencing and molecular profiling can clarify histologic origin and occasionally inform management.
Molecular diagnostics are not routinely used for common benign cysts, but they are evolving tools for complex cases or when fertility preservation strategies require additional risk stratification.

Impact on practice

Better biomarker algorithms reduce diagnostic uncertainty, support conservative management in many patients, and help identify those who require referral to gynecologic oncology. A balanced interpretation that accounts for pretest probability is essential to avoid overuse of testing.

ACOG and major centers provide guidance on appropriate use of tumor markers in adnexal mass evaluation (ACOG; Mayo Clinic).

H2: Fertility-sparing strategies and fertility preservation

Preservation of fertility and ovarian endocrine function is a central consideration when treating benign ovarian tumors in reproductive-age patients.

Ovarian-sparing surgery

Cystectomy (enucleation of the cyst) is preferred over oophorectomy for benign lesions when technically feasible.
Techniques that minimize excision of healthy ovarian cortex and limit thermal injury reduce the decline in ovarian reserve; use of fine dissection, meticulous hemostasis, and judicious use of energy devices is encouraged.

Timing and counseling

Preoperative counseling should include discussion of fertility goals, risk to ovarian reserve, AMH testing, and possible need for assisted reproductive technologies.
In some cases of large or recurrent lesions where ovarian preservation is unsafe, oophorectomy may be necessary; fertility preservation options should be discussed proactively.

Assisted reproductive technologies and cryopreservation

Oocyte or embryo cryopreservation is the established fertility-preserving option when ovarian function is at substantial risk.
Ovarian tissue cryopreservation is an option in select circumstances (e.g., patients who cannot delay therapy or when gonadotoxic treatment is planned); reported live births after ovarian tissue transplantation support this as an emerging option but it remains less widely available.
Collaboration with reproductive endocrinology and infertility specialists is recommended for individualized planning.

ACOG and reproductive medicine guidelines outline fertility-preservation options and counseling strategies for women facing surgery or other treatments that risk ovarian function (ACOG; Mayo Clinic).

H2: Enhanced recovery protocols, outpatient surgery, and opioid-sparing analgesia

Perioperative care has evolved to promote rapid recovery and reduce hospitalization.

Enhanced Recovery After Surgery (ERAS)

ERAS pathways specific to gynecologic procedures include preoperative counseling, multimodal analgesia, avoidance of prolonged fasting, optimized fluid management, and early mobilization.
Implementation of ERAS is associated with shorter length of stay, decreased opioid use, and quicker return to baseline function.

Same-day discharge and outpatient laparoscopy

Many laparoscopic adnexal surgeries can be performed safely with same-day discharge for appropriately selected patients under ERAS pathways and robust outpatient support.
Selection criteria include absence of major comorbidities, adequate home support, and proximity to care if complications arise.

Opioid-sparing pain management

Multimodal analgesia (acetaminophen, NSAIDs, regional anesthesia techniques) reduces opioid requirements and related adverse effects.
Patient education about realistic expectations for postoperative pain and activity is central to successful outpatient care.

Mayo Clinic and Cleveland Clinic resources describe practical perioperative strategies for gynecologic surgery and patient recovery (Mayo Clinic; Cleveland Clinic).

H2: Reducing unnecessary surgery — surveillance strategies and shared decision-making

A critical public-health objective is to reduce unnecessary surgery for benign disease while ensuring safe care for malignancy. Advances in 2024 emphasize risk-adapted surveillance and shared decision-making.

Observation protocols

Small simple cysts (e.g., <5–7 cm in premenopausal women) with benign ultrasound features and reassuring clinical context are often managed with interval surveillance and repeat imaging rather than immediate surgery.
Endometriomas and dermoid cysts may be observed if asymptomatic and stable, with timing of intervention guided by symptoms, size progression, and fertility plans.

Multidisciplinary review and referral pathways

Indeterminate or high-risk lesions benefit from multidisciplinary input, including gynecology, gynecologic oncology, radiology, and reproductive specialists.
Clear referral criteria to gynecologic oncology reduce missed malignancies and optimize care for those who need oncologic surgery.

Patient-centered counseling

Shared decision-making tools that present the risks and benefits of observation versus surgery, including the potential impact on fertility and quality of life, improve patient satisfaction and adherence to management plans.

A significant 2023 study highlighted that many surgeries for adnexal masses involve benign disease; improved triage and surveillance can reduce this burden (BMC Ovarian Research, 2023). National clinical resources (ACOG; NIH/MedlinePlus) support conservative management in appropriate circumstances.

H2: Artificial intelligence in clinic workflow and predictive modeling

Beyond imaging interpretation, AI and predictive analytics are increasingly integrated into clinic workflows:

Electronic health record–integrated risk calculators combine demographic data, symptoms, biomarkers, and imaging descriptors to generate individualized management suggestions.
Decision-support tools help clinicians adhere to guideline-based surveillance intervals and triage patients for specialty referral.
Ongoing research and validation are required to ensure equitable performance across diverse patient populations.

NIH-funded research consortia and institutional initiatives are testing AI applications; adoption should follow rigorous validation and transparent reporting of model performance (NIH/NCBI).

H2: Future directions and ongoing research

Several areas are priorities for research and clinical translation:

Robust randomized trials comparing percutaneous ablation techniques and HIFU with standard surgical approaches for selected benign lesions.
Long-term fertility and endocrine outcomes following novel ablative therapies.
Large multicenter validation of AI tools and imaging-based scoring systems across diverse practice settings.
Biomarker discovery to differentiate benign proliferative lesions from early malignancy with high specificity.
Cost-effectiveness analyses of robotic surgery and high-technology interventions versus conventional laparoscopy.

ClinicalTrials.gov and NIH research updates summarize ongoing studies and emerging evidence in these areas.

H2: Practical takeaways for clinicians and patients

Most ovarian masses are benign; careful evaluation by history, physical, imaging, and judicious use of biomarkers guides management (ACOG; NIH/MedlinePlus).
When intervention is needed, minimally invasive surgery (laparoscopy or robotic-assisted laparoscopy) with ovarian-sparing techniques is standard for benign disease and is associated with favorable recovery metrics (Mayo Clinic; Cleveland Clinic).
Emerging noninvasive modalities such as HIFU and image-guided ablation hold promise but remain investigational for ovarian tumors; these should be considered within clinical trials or specialized centers.
Advances in imaging (O-RADS, MRI) and AI-assisted triage decrease unnecessary operations by improving preoperative characterization.
Fertility preservation must be discussed preoperatively for reproductive-age patients; collaboration with reproductive specialists is recommended.
ERAS pathways, opioid-sparing anesthesia, and same-day discharge protocols improve postoperative recovery and patient experience.
Shared decision-making and risk-adapted surveillance reduce overtreatment while maintaining patient safety.

For patient-facing information and practical guidance, consult ACOG’s resources on adnexal masses, MedlinePlus (NIH) information on ovarian cysts, and clinical overviews from Mayo Clinic and Cleveland Clinic (ACOG; NIH/MedlinePlus; Mayo Clinic; Cleveland Clinic).

H2: Conclusion

The year 2024 has seen meaningful incremental advances in the diagnosis and management of benign ovarian tumors. Improvements in minimally invasive surgical technique, perioperative care, imaging characterization, biomarker use, and early exploration of noninvasive ablative technologies are converging to provide safer, more fertility-sparing, and more patient-centered care. Continued high-quality research, multidisciplinary collaboration, and careful implementation of new technologies are essential to translate these advances into consistent improvements in outcomes for the broad population of women affected by benign ovarian disease.

References and further reading:

ACOG – Adnexal masses: https://www.acog.org/womens-health/faqs/adnexal-masses
NIH / MedlinePlus – Ovarian cysts: https://medlineplus.gov/ovariancysts.html
Mayo Clinic – Ovarian cysts: Diagnosis and treatment: https://www.mayoclinic.org/diseases-conditions/ovarian-cysts/diagnosis-treatment/drc-20353405
Cleveland Clinic – Ovarian cysts: https://my.clevelandclinic.org/health/diseases/15327-ovarian-cysts
Zhou S, et al. (2023). Surgical management of adnexal masses: rates of malignant disease and implications for practice. BMC Ovarian Research: https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-023-01336-6
NIH ClinicalTrials and NCBI resources on HIFU and ablative technologies in gynecology: https://clinicaltrials.gov and https://www.ncbi.nlm.nih.gov/ (search terms: “high-intensity focused ultrasound gynecology”, “ovarian cyst ablation”)